SECsense Logo

Vaxart, Inc. Unveils Key Insights in Form 8-K Filing - February 2025 Update

$VXRT
Form 8-K
Filed on: 2025-02-24
Source
Vaxart, Inc. Unveils Key Insights in Form 8-K Filing - February 2025 Update

Based on the provided section of the financial report, here are the key pieces of information extracted:

  1. Company Information:
  • Name: Vaxart, Inc.
  • State of Incorporation: Delaware (DE)
  • CIK (Central Index Key): 0000072444
  • Address: 170 Harbor Way, Suite 300, South San Francisco, CA 94080
  • Phone Number: 650-550-3500
  1. Reporting Details:
  • Filing Type: Form 8-K
  • Filing Date: February 21, 2025
  • Period of Report: February 21, 2025
  1. Securities Information:
  • Common Stock Symbol: VXRT
  • Stock Exchange: NASDAQ
  • SEC File Number: 001-35285
  • IRS Employer Identification Number: 59-1212264
  1. XML and XBRL Metadata:
  • The document is structured in XBRL (eXtensible Business Reporting Language), which is a format for transmitting financial data.
  • The schema reference indicates the specific structure and elements that this filing adheres to, with the file vxrt-20250221.xsd.

Insights:

  • The filing is likely related to a significant event or information that Vaxart, Inc. deems necessary to disclose to shareholders and the SEC, as indicated by the use of Form 8-K.
  • The date of the report suggests it may be related to events occurring on or around February 21, 2025, which could be crucial for investors and analysts focusing on the company's performance or strategic developments at that time.
  • Vaxart, Inc. operates in the biotechnology sector, which typically involves high volatility and potential for rapid changes based on research and development outcomes, regulatory approvals, and market dynamics.

Overall, this document provides essential information regarding Vaxart's corporate identity, filing specifics, and the context for further analysis of its financial and operational performance.